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A possible role of Snap25 polymorphisms in type 2 diabetes mellitus (T2DM)was evaluated by analyzing three SNPs within intron 1
in a region known to affect the gene expression in vitro. Genomic DNA from 1019 Saudi individuals (489 confirmed T2DM and 530
controls) was genotyped for SNPs rs363039, rs363043, and rs363050 in Snap25 using the TaqMan Genotyping Assay. Significantly
higher levels of fasting glucose andHbA1c were detected in T2DMpatients carrying the rs363050 (AG/GG) genotypes compared to
the (AA) genotype (𝑓 = 4.41, 𝑑𝑓 = 1, and 𝑝 = 0.03 and 𝑓 = 5.31, 𝑑𝑓 = 1, and 𝑝 = 0.03, resp.). In these same patients, insulin levels
were significantly decreased compared to the (AA) individuals (𝑓 = 7.29, 𝑑𝑓 = 1, and 𝑝 = 0.009). Significant associations were
detected between rs363050 (AG/GG) genotypes and increasing fasting glucose levels (𝑝 = 0.01 and OR: 1.05), HbA1c levels (OR:
5.06 and 𝑝 = 0.02), and lower insulinemia (𝑝 = 0.03 and OR: 0.95) in T2DMpatients.Theminor Snap25 rs363050 (G) allele, which
results in a reduced expression of Snap25, is associated with altered glycemic parameters in T2DM possibly because of reduced
functionality in the exocytotic machinery leading to suboptimal release of insulin.
1. Introduction
Blood glucose levels are regulated by insulin release from
pancreatic 𝛽-cells via exocytosis, a fine-tuned mechanism
mediated by complex machinery. During the exocytotic
process secretory granules (SG) of insulin fuse with the
plasma membrane; this process is mediated by a number
of key players including the soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE)
proteins. The SNARE-complex includes the two t-SNARE
proteins, synaptosomal protein of 25 kDa (Snap25) and
syntaxin 1A, as well as the v-SNARE protein VAMP2. To
allow exocytosis the amino terminal of Snap25 binds to
syntaxin 1A and the carboxy-terminal binds to VAMP2,
forming the four-helical bundle that brings SG in close
contact with the plasma membrane, thus enabling fusion to
occur. Snap25 is contained in insulin-secreting cells [1] and
is known to modulate several processes apart from the actual
fusion event, including the activity of potassium voltage
gated (Kv)2.1 channels [2]. Notably, Kv2.1 is the prevalent
Kv channel in neuroendocrine and endocrine cells, and
the Kv2.1 current repolarizes 𝛽-cell action potentials upon
exposure to glucose to limit Ca2+ entry and insulin secretion.
Because of the pivotal role of Snap25 in insulin release
[2–6] we evaluated a possible role of three Snap25 polymor-
phisms (rs363039, rs363043, and rs363050) that are localized
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within intron 1 in a region spanning about 13.8 kb and are
known to affect the gene expression in vitro [7, 8], in type
2 diabetes mellitus (T2DM). To this end, fasting glycemia,
insulinemia, and the concentration of glycated haemoglobin
(HbA1c) were correlated with Snap25 polymorphisms in 489
patients with a diagnosis of type 2 diabetes mellitus (T2DM)
and 530 age- and sex-matched healthy controls (HC).
2. Methods
2.1. Patients and Controls. A total of 1019 unrelated adult
Saudi individuals (489 confirmed T2DM (280 males and 209
females) and 530 controls (319 males and 211 females)) were
randomly selected from the Biomarker Screening Project
in Riyadh (Riyadh Cohort), a capital-wide epidemiological
study of over 17,000 consenting Saudis coming from different
Primary Health Care Centers (PHCCs) in Kingdom of Saudi
Arabia (KSA). Written informed consent was obtained from
all participants before inclusion in the study. The research
was approved by the Ethics Committee of the College of
Science, King SaudUniversity, Riyadh, KSA, and themethods
were carried out in accordance with the approved guidelines.
Diagnosis of T2DMwas based onWorldHealthOrganization
(WHO) proposed cut-off: fasting plasma glucose > or =
7.0mmol/L or 126mg/dL. Subjects with comorbidities that
needed medical attention or with medical complications
(coronary artery disease, nephropathy, thyroid diseases, and
end stage renal or liver disease) were excluded from the
study. Consenting participants were then requested to visit
the nearest participating PHCC for questionnaire adminis-
tration, anthropometric measurement, and blood extraction.
A questionnaire focusing on demographic information and
past and present medical history was given to all subjects.
2.2. Anthropometry, Blood Collection, and Biochemical Analy-
ses. Subjects were requested to visit their respective PHCCs
following overnight fasting (>10 hours) for anthropome-
try and blood withdrawal. Anthropometry included height
(rounded off to the nearest 0.5 cm), weight (rounded off to
the nearest 0.1 kg), waist andhip circumference (centimeters),
and mean systolic and diastolic blood pressure (millimeters
of Hg) (average of 2 readings). Body mass index (BMI) was
calculated as weight in kilograms divided by height in square
meters. Fasting glucose and lipid profile weremeasured using
a chemical analyzer (Konelab, Espoo, Finland). Serum insulin
was assessed using an enzyme-linked immunosorbent assay
(ELISA)with an intra-assay variability of<10% and interassay
variation of<15%. All fasting samples fell within the detection
range.
2.3. Snap25 Genotyping. Genomic DNA was isolated from
whole blood using the blood genomicPrep mini spin kit
(GE Healthcare Life Sciences, Piscataway, NJ, USA). SNPs
rs363043, rs363039, and rs363050 located in intron 1 of
Snap25 gene were genotyped using the TaqMan SNP Geno-
typing Assays (Applied Biosystems by Life Technologies,
Foster City, CA, USA) on an ABI PRISM 7000 Sequence
Detection System.
Table 1: Clinical characteristic of the T2DMpatients and the healthy
controls enrolled in the study.
Healthy controls T2DM
𝑁 530 489
Gender male/female 319/211 280/209
Age (years) 48.5 ± 12.5 51.2 ± 11.5
Systolic BP (mmHg) 117.6 ± 12.3 129.7 ± 15.1∗
Diastolic BP (mmHg) 75.7 ± 8.4 80.7 ± 8.9∗
BMI (kg/m2) 28.8 ± 7.4 32.0 ± 5.9∗
Hip circumference (cm) 87.1 ± 22.0 98.0 ± 24.2∗
Waist circumference (cm) 98.5 ± 25.0 103.0 ± 26.9∗
Total cholesterol (mmol/L) 5.1 ± 1.0 5.3 ± 1.2∗
Fasting glucose (mmol/L) 5.1 ± 0.9 12.0 ± 4.7
HbA1c (IU) 5.2 ± 0.5 7.5 ± 1.3∗
Insulinemia 𝜇U/mL 11.2 ± 18.2 18.4 ± 17.7∗∗
LDL-cholesterol (mmol/L) 3.4 ± 0.9 3.5 ± 1.0
HDL-cholesterol (mmol/L) 0.9 ± 0.4 0.8 ± 0.3∗
Triglycerides (mmol/L) 1.5 ± 0.8 2.2 ± 1.3∗
Median values ± standard deviation (SD) are shown. Statistically significant
differences are indicated: ∗𝑝 < 0.001; ∗∗𝑝 < 0.05.
2.4. Statistical Analysis. TheKolmogorov-Smirnov (K-S) test
was applied to verify normal distribution of numerical vari-
able scores. All numerical scores resulted in being normally
distributed, and they were shown as mean and standard
deviation (SD). Hardy-Weinberg equilibrium was tested
using Chi-square test. ANOVA calculation was performed to
analyse biochemical parameters in relationship with Snap25
genotypes stratified for T2DM and HC. Moreover multi-
variate stepwise logistic regression analysis was performed,
using Snap25 polymorphisms as responsible variables and
age, gender, and BMI as covariates.
3. Results and Discussion
Fasting glycemia, insulinemia, and the concentration of
glycated haemoglobin (HbA1c) were correlated with Snap25
polymorphisms in 489 patients with a diagnosis of T2DM
and 530 age- and sex-matched HC (Table 1), whereas no
differences were seen in the distribution of the 3 Snap25 SNPs
between T2DM and controls (data not shown). Significantly
higher levels of fasting glucose and HbA1c were detected
in T2DM patients carrying the rs363050 (AG/GG) (57%
of cases) genotypes compared to those carrying the (AA)
genotype (43% of cases) (𝑓 = 4.41, 𝑑𝑓 = 1, and 𝑝 = 0.03 and
𝑓 = 5.31, 𝑑𝑓 = 1, and 𝑝 = 0.03, resp.). In these same patients
insulin levels were significantly decreased as well compared
to the (AA) individuals (𝑓 = 7.29, 𝑑𝑓 = 1, and𝑝 = 0.009)
(Table 2). In contrast with these results, no associations were
observed between any of the Snap25 genotypes and glycemic
parameters in HC (𝑓 = 0.88, 𝑑𝑓 = 1, and𝑝 = 0.35).
The correlation between the rs363050 (G) minor allele
and altered glycemic parameters in T2DM patients was
even stronger when multivariate stepwise logistic regression
analysis was performed. Thus, when rs363050 (AG/GG)
versus (AA) was calculated as the responsible variable and
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Table 2: Glycemic parameters in 489 T2DM patients according to
the Snap25 rs36305 genotype.
Snap25 rs363050 genotype
AA AG + GG
Fasting glucose (mmol/L) 11.5 ± 4.3∗∗ 12.9 ± 4.9∗∗
HbA1c (IU) 6.9 ± 0.9∗∗ 8.2 ± 1.4∗∗
Insulinemia 𝜇U/mL 23.9 ± 23.1∗ 13.4 ± 8.1∗
Median values ± standard deviation (SD) are shown. Statistically significant
differences are indicated: ∗𝑝 < 0.001; ∗∗𝑝 < 0.05.
age, gender, and BMI were calculated as covariates, a statisti-
cally significant association was detected between (AG/GG)
genotypes and increasing fasting glucose levels (𝑝 = 0.01,
OR: 1.05), with a higher risk in female versus male patients
(𝑝 = 0.03, OR: 1.63). A similar association was observed as
well between the (AG/GG) genotypes and increasing HbA1c
levels (𝑝 = 0.02, OR: 5.06) and between these genotypes and
lower insulinemia (𝑝 = 0.03, OR: 0.95) in T2DM patients
after adjustment for BMI, gender, and age covariates, even if
in this case no specific risk was detected in female patients.
Again, no such associations were observed in healthy con-
trols. To rule out a possible role played by confounding
factors, diabetes duration, hypoglycemic drug use, insulin
resistance condition, and anthropometric parameters were
compared between patients carrying the two genotypes, and
no significant differences emerged (data not shown).
Insulin secretion depends on the integrity of the SNARE
exocytotic machinery, as shown by the observation that
decreased expression of t-SNARE associates with an alter-
ation of this process [5]. Snap25, a protein that is expressed
in pancreatic endocrine cells, is an essential component of
such machinery [4]. Data herein shows that the Snap25
rs363050 (G) allele correlates with increasing glycemia and
HbA1c concentration, as well as with reduced insulinemia
in T2DM patients alone; this allele was recently demon-
strated to be associated with a significantly reduced gene
expression in vitro compared to the rs363050 (A) allele
[8]. Because no associations between glycemic parameters
and Snap25 polymorphism were detected in healthy controls
this polymorphism is not likely to be a genetic risk factor
for T2DM by itself but rather to correlate with altered
T2DM-related metabolic parameters once T2DM has been
diagnosed. This effect is possibly mediated by impairment
in the SNARE complex, resulting in a reduced functionality
of the exocytotic machinery and, as a consequence, in a
suboptimal release of insulin.
4. Conclusions
Snap25 plays an important role in exocytosis, and its poly-
morphisms have been implicated in modulating the release
of neurotransmitters in a number of neurologic conditions
including autism and Alzheimer’s disease (AD) [9]. Impor-
tantly, the integrity of the insulin signaling plays a pivotal role
for cognitive function andmemory.Thus, in neurons, insulin
stimulates growth, survival, differentiation, metabolism,
protein synthesis, synapse formation, and plasticity [10].
The preliminary results herein indicate that the same Snap25
SNPs are present in AD and in T2DM; these data add further
evidence to the importance played by an intact insulin signal-
ing pathway in the maintenance of well-structured cognitive
functions and reinforce the idea that Snap25 polymorphisms
play a role in metabolic disorders. Notably, polymorphisms
in the human Snap25 gene have been associated with weight
gain after antipsychotic treatment and with altered levels of
serum triglycerides [11, 12] and, importantly, with the severity
of metabolic syndrome in T2DM [13] These data, finally,
confirm previous results showing a role of Snap25 in insulin
secretion [2–6]. Because the incidence of AD is increased
in T2DM [14] it will be interesting to explore whether
Snap25 alleles-mediated exocytosis alterations bridge these
two pathologies, possibly predicting those T2DM patients
with a higher risk of developing AD.
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